Signet Financial Management LLC Has $396,000 Stake in Abbott Laboratories (NYSE:ABT)

Signet Financial Management LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABTFree Report) by 44.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,601 shares of the healthcare product maker’s stock after selling 2,930 shares during the quarter. Signet Financial Management LLC’s holdings in Abbott Laboratories were worth $396,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Main Street Research LLC boosted its holdings in Abbott Laboratories by 5.0% in the fourth quarter. Main Street Research LLC now owns 3,868 shares of the healthcare product maker’s stock valued at $426,000 after acquiring an additional 183 shares during the last quarter. Riverstone Advisors LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $225,000. Octavia Wealth Advisors LLC raised its position in Abbott Laboratories by 5.4% in the 4th quarter. Octavia Wealth Advisors LLC now owns 3,520 shares of the healthcare product maker’s stock valued at $387,000 after buying an additional 181 shares during the last quarter. First American Trust FSB raised its position in Abbott Laboratories by 53.4% in the 4th quarter. First American Trust FSB now owns 152,022 shares of the healthcare product maker’s stock valued at $16,733,000 after buying an additional 52,899 shares during the last quarter. Finally, Grant GrossMendelsohn LLC raised its position in Abbott Laboratories by 3.2% in the 4th quarter. Grant GrossMendelsohn LLC now owns 12,446 shares of the healthcare product maker’s stock valued at $1,394,000 after buying an additional 388 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ABT. Barclays raised their target price on Abbott Laboratories from $133.00 to $141.00 and gave the company an “overweight” rating in a research report on Friday, January 26th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $128.00 target price on shares of Abbott Laboratories in a research report on Wednesday, February 14th. Citigroup raised their target price on Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. TheStreet upgraded Abbott Laboratories from a “c+” rating to a “b-” rating in a research note on Thursday, December 21st. Finally, Raymond James increased their price target on Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $122.14.

Get Our Latest Stock Analysis on ABT

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 42,500 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the sale, the executive vice president now directly owns 65,027 shares in the company, valued at $7,315,537.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Abbott Laboratories news, EVP Andrea F. Wainer sold 42,500 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the sale, the executive vice president now directly owns 65,027 shares in the company, valued at $7,315,537.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Andrea F. Wainer sold 12,500 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total value of $1,500,000.00. Following the completion of the sale, the executive vice president now owns 78,704 shares in the company, valued at $9,444,480. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,435 shares of company stock valued at $6,451,298. Insiders own 0.47% of the company’s stock.

Abbott Laboratories Stock Up 0.3 %

ABT stock opened at $109.20 on Wednesday. The stock has a market capitalization of $189.48 billion, a P/E ratio of 33.50, a P/E/G ratio of 2.62 and a beta of 0.74. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16. The business has a fifty day moving average price of $114.57 and a 200-day moving average price of $107.60. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64.

Abbott Laboratories (NYSE:ABTGet Free Report) last released its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.19. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. The firm had revenue of $10.24 billion during the quarter, compared to analyst estimates of $10.19 billion. During the same quarter in the prior year, the company posted $1.03 earnings per share. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. Equities analysts forecast that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.01%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s payout ratio is presently 67.48%.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Featured Stories

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.